Research location
Grieskirchen
Austria
Advertisement
Research activity in Grieskirchen
AustriaCureCurrent currently publishes aggregate city-level research activity for this location: 17 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Grieskirchen
17 linked trials · page 1 of 1A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · 2021-07-14 · 1 site observation
TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 1 site observation
TERMINATED
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD PatientsNCT04072887 · 2019-09-12 · 1 site observation
COMPLETED
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsNCT04053634 · 2019-08-26 · 1 site observation
COMPLETED
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaNCT02571777 · 2015-12-08 · 1 site observation
COMPLETED
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20 · 1 site observation
COMPLETED
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation
COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02164513 · 2014-06-30 · 1 site observation
COMPLETED
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)NCT02006732 · 2013-11-01 · 1 site observation
COMPLETED
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT01908140 · 2013-09-01 · 1 site observation
COMPLETED
Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®NCT01803555 · 2013-07-04 · 1 site observation
COMPLETED
Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller MedicationNCT01696071 · 2012-09-01 · 1 site observation
COMPLETED
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.NCT01533935 · 2012-02-01 · 1 site observation
COMPLETED
Dose Finding Study for QAW039 in AsthmaNCT01437735 · 2011-08-01 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical PracticeNCT01061567 · 2009-11-01 · 1 site observation
COMPLETED
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole TreatmentNCT00651183 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.